novo nordisk semaglutide patent FTC Warns on Inaccurate Patents for Ozempic The upcoming expiry of the

Consider Semaglutide as a Treatment Option: The healthcare provider will evaluate whether semaglutide is an appropriate treatment option based on factors such as your BMI, weight-related health conditions, previous weight loss attempts, and health status

This package includes our weight loss program, diet and exercise guides, 24/7 access to on-call doctors, and comprehensive care

Semaglutide in other indications, source: Novo Nordisk official website Heart failure with preserved ejection fraction (HFpEF) On August 8, 2023, NovoNordisk announced results from the SELECT clinical phase 3 trial of semaglutide

Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [Press release]

Not vague advice

Partner Nils Braun represented the client at the Boards of Appeal in the case of EP 845 and EP 885.